Yearly Archives: 2022

NEWPORT BEACH, CA – GABA Therapeutics, Inc has successfully completed the single ascending dose (SAD) stage of its Phase 1 study of GRX-917 in Melbourne, Australia. Interim data from the SAD stage showed that GRX-917 was well tolerated and favorable safety results were observed up to 500mg. Furthermore, the results [...]

NEWPORT BEACH, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- GABA Therapeutics, Inc, (“GABA”) a clinical-stage biotechnology company developing novel therapies for anxiety, depression and other neurological disorders, and part of the atai Life Sciences (“atai”) platform, announces the appointment of Mario David Saltarelli M.D., Ph.D. as Chief Executive Officer [...]